Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
136-150 of 4175 results
Medivir’s CTCL drug remetinostat yields positive data in phase II study
Medivir has reported positive data from its phase II clinical trial of the topical, skin-directed histone deacetylase (HDAC) inhibitor, remetinostat, in early stage Cutaneous T-cell Lymphoma patients.
Contract Research & Services > Clinical Trials > News
Burosumab’s pediatric phase 2 studies in X-linked hypophosphatemia yield positive results
Ultragenyx Pharmaceutical and Kyowa Kirin International (KKI), a subsidiary of Kyowa Hakko Kirin (Kyowa Hakko Kirin), have reported positive 64-week data from a pediatric Phase 2 study of burosumab (KRN23) for X-linked hypophosphatemia (XLH) treatment in children aged between five and 12 years.
Contract Research & Services > Clinical Trials > News
Allergan to advance Botox trial to third phase for treatment of depression
By PBR Staff Writer
Allergan announced to advance its wrinkle treatment Botox to third phase after its phase II study showed a partial benefit in treating patients with major depressive disorder (MDD).
Contract Research & Services > Clinical Trials > News
Verona doses first patient in cystic fibrosis trial of RPL554
Verona Pharma has enrolled and dosed the first patient in a Phase 2a clinical study to evaluate RPL554, as a treatment option for cystic fibrosis (CF).
Contract Research & Services > Clinical Trials > News
Paratek’s pneumonia antibiotic succeeds in phase 3 trial
By PBR Staff Writer
A phase 3 study of Paratek Pharmaceuticals' omadacycline has met its primary and secondary endpoints in the treatment of patients with community-acquired bacterial pneumonia (CABP).
Contract Research & Services > Clinical Trials > News
GSK commences phase III study of mepolizumab in severe HES patients
By PBR Staff Writer
GlaxoSmithKline (GSK) has initiated a phase III study of its interleukin 5 (IL-5) antagonist, mepolizumab in hypereosinophilic syndrome (HES) patients.
Contract Research & Services > Clinical Trials > News
Amgen, UCB explore option of second course of treatment with evenity
Amgen and UCB have released results from the fourth year of a Phase 2 study demonstrating the safety and efficacy of a second course of treatment with evenity (romosozumab), an investigational candidate for postmenopausal women with osteoporosis.
Contract Research & Services > Clinical Trials > News
Corbus’ anabasum meets safety and tolerability goals in cystic fibrosis study
By PBR Staff Writer
A phase 2 trial evaluating Corbus Pharmaceuticals’ multiple doses of anabasum (Resunab) has met its primary objective in patients with cystic fibrosis, demonstrating an acceptable safety and tolerability profile with no severe adverse events.
Contract Research & Services > Clinical Trials > News
Ritter reports topline phase 2b/3 results for lactose intolerance treatment RP-G28
Ritter Pharmaceuticals' lactose intolerance treatment, RP-G28, demonstrated efficacy and clinically meaningful benefit in phase 2b/3 clinical trial.
Contract Research & Services > Clinical Trials > News
Summit to extend PhaseOut DMD trial for ezutromid
Summit Therapeutics has announced that, subject to regulatory approval, it will go ahead with the planned extension phase of PhaseOut DMD, a Phase 2 clinical trial studying the utrophin modulator ezutromid.
Contract Research & Services > Clinical Trials > News
Allergan, Paratek’s acne drug succeeds in two phase 3 trials
By PBR Staff Writer
Allergan and Paratek Pharmaceuticals’ acne drug sarecycline has met its primary efficacy endpoints in two phase 3 trials.
Contract Research & Services > Clinical Trials > News
Xenon’s acne drug XEN801 fails in phase 2 trial
By PBR Staff Writer
A phase 2 trial of Xenon Pharmaceuticals’ acne drug XEN801 has failed to meet its efficacy endpoints in patients having moderate to severe acne.
Contract Research & Services > Clinical Trials > News
Akashi gets FDA nod to restart clinical development of DMD drug HT-100
Akashi Therapeutics has secured approval from the US Food and Drug Administration (FDA) to resume clinical development of HT-100 (delayed-release halofuginone) in patients with any of the genetic mutations that cause Duchenne muscular dystrophy (DMD).
Contract Research & Services > Clinical Trials > News
Novartis’ serelaxin fails to meet primary endpoint in heart failure study
By PBR Staff Writer
Novartis' RLX030 (serelaxin) has failed to meet its primary endpoint in a phase III acute heart failure (AHF) study.
Contract Research & Services > Clinical Trials > News
Lilly’s abemaciclib meets primary endpoint in phase 3 breast cancer trial
By PBR Staff Writer
A phase 3 study of Lilly’s breast cancer drug, abemaciclib, in combination with fulvestrant, has met its primary endpoint of progression-free survival (PFS).
Contract Research & Services > Clinical Trials > News
136-150 of 4175 results